Miaozhikang Secures Tens of Millions in Angel Funding to Advance Digital Chronic Disease Management
VCBeat has learned that Zhejiang Miaozhikang Health Technology Co., Ltd. (“Miaozhikang”) recently completed an angel round of financing amounting to tens of millions of yuan, exclusively invested by Jiuwei Capital.
Miaozhikang is a platform-based enterprise specializing in the reversal of diabetes and obesity-related conditions (such as obesity, fatty liver disease, and polycystic ovary syndrome). Leveraging 5G communication technology and adopting a multidisciplinary, personalized management model, it has developed the “Miaozhikang APP” to provide the public with comprehensive, open, smart, and personalized digital health management services for diabetes and obesity-related diseases.
Miaozhikang was founded by Shan Pengfei, a chief physician at the Second Affiliated Hospital of Zhejiang University School of Medicine and project leader for national-level continuing medical education programs. The company has assembled an interdisciplinary team integrating medicine, engineering, and informatics, with experts in endocrinology, psychology, sports medicine, nutrition, computer science, and artificial intelligence. It was selected as a talent-led entrepreneurial project under Hangzhou’s “5050 Plan” in 2021.
Miaozhikang adheres to the concept of integrating industry, academia, and research, collaborating with the Binjiang Institute of Zhejiang University to translate the “new technology for diabetes reversal” into practical applications. Application data provided by the company shows that users of the “Miaozhikang APP” achieve an average weight loss of approximately 17% over 4–5 months, enabling rapid and efficient reversal of conditions such as diabetes and fatty liver disease. This helps reduce diabetic complications and extend patient life expectancy.
Regarding this round of financing, Shan Pengfei stated“Diabetes is a disease that poses a serious threat to human health. The ‘Outline of the Healthy China 2030 Plan’ and the ‘Healthy China Action (2019–2030)’ have incorporated diabetes prevention and control into the national overall prevention and control strategy. We thank the investors for their recognition and support of Miaozhikang. We believe that following this round of financing, Miaozhikang will achieve rapid development and further contribute to the management of chronic diseases such as diabetes in China.”
Zhejiang Jiuwei Private Equity Fund Management Co., Ltd. (Registration No.: P1064271) is a member of the Zhejiang Equity Investment Industry Association. The company was established by shareholders comprising well-known domestic industry leaders and several senior professionals from the financial capital sector, and has issued more than 10 funds to date. Its invested projects include Chuangyuan Instrument (831961), Demai Shi (301007), Xinhua Shares (603867), Lingxin Shares (831129), Bohui Shares (300839), Xintong Electronics (831427), Tianhong Lithium Battery (873152), Nanlin Electronics (831394), Ansys China, Huicang Technology, Chaoteng Energy, Hanerm, Zhuoyi Biology, and Pengyang Medical.